Senores Pharmaceuticals SENORES
Young US-focused generics company with an Atlanta (US) manufacturing site plus emerging-market and critical-care injectables
Mapped in 1 theme: Pharmaceuticals.
Where Senores Pharmaceuticals sits in the supply chain
Senores Pharmaceuticals appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Generics (US & export)
Emerging entrantOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 215 | 398 | 633 |
| Net profit | 33 | 58 | 122 |
Latest-year revenue ₹633 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- US-based plant (Atlanta) qualifies for US government contracts and is a natural tariff hedge
- Fast growth from a small base (FY26 revenue ₹633 Cr, PAT ₹122 Cr)
Risks
- Small scale and short listed history (Dec 2024)
- Depends on partner-led US launches and acquisitions
Common questions
What does Senores Pharmaceuticals do?
Young US-focused generics company with an Atlanta (US) manufacturing site plus emerging-market and critical-care injectables.
Where does Senores Pharmaceuticals sit in the supply chain?
Senores Pharmaceuticals (NSE: SENORES) is mapped in 1 supply-chain layer: Generics (US & export) (Pharmaceuticals).
Who are Senores Pharmaceuticals' peers?
In the Generics (US & export) layer of Pharmaceuticals: Dr Reddy's Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, Sun Pharmaceutical Industries and 6 more.
What is Senores Pharmaceuticals' market cap and valuation?
As of 30 Oct 2026: market cap ₹5,225 Cr, P/E 39.1x, ROCE 15.1%, ROE 13.4%, dividend yield 0%.